دورية أكاديمية
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
| العنوان: | Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. |
|---|---|
| المؤلفون: | Hailemichael Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Precision Cancer Therapies Program, Department of Hematology and Medical Oncology, Ochsner Health, New Orleans, LA, USA., Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Rheumatology and Rehabilitation, Assiut University Hospitals, Faculty of Medicine, Assiut University, Egypt., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daher M; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saberian C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ogata D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim ST; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nurieva R; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Abu-Sbeih H; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fa'ak F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mathew A; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Falohun A; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Trinh V; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zobniw C; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Spillson C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Awiwi M; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elsayes K; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soto LS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melendez BD; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Curry J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ekmekcioglu S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: adiab@mdanderson.org. |
| المصدر: | Cancer cell [Cancer Cell] 2022 May 09; Vol. 40 (5), pp. 509-523.e6. Date of Electronic Publication: 2022 May 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge, Mass. : Cell Press, c2002- |
| مواضيع طبية MeSH: | Colitis*/chemically induced , Neoplasms*/drug therapy, Animals ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy ; Interleukin-6 ; Mice ; Myeloid Cells |
| مستخلص: | Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil, and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1). Anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) induced stronger Th17 memory in colitis than anti-program death 1 (anti-PD-1). In murine models, IL-6 blockade associated with improved tumor control and a higher density of CD4 + /CD8 + effector T cells, with reduced Th17, macrophages, and myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) model with tumors, combined IL-6 blockade and ICB enhanced tumor rejection while simultaneously mitigating EAE symptoms versus ICB alone. IL-6 blockade with ICB could de-couple autoimmunity from antitumor immunity. Competing Interests: Declaration of interests A.D. received Institution Research funds: Bristol Myers and Squibb, Merck, Pfizer, Nektar Therapeutics, Idera Pharmaceuticals, Apexigen and advisory board fees: Bristol Myers and Squibb, Nektar Therapeutics, Idera Pharmaceuticals, Iovance Therapeutics, Apexigen. M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, and ABM Therapeutics. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| التعليقات: | Comment in: Cancer Cell. 2022 May 9;40(5):450-451. (PMID: 35537409) |
| References: | Nature. 2006 May 11;441(7090):235-8. (PMID: 16648838) Nature. 2019 May;569(7756):428-432. (PMID: 31043740) Int Immunol. 2011 Dec;23(12):751-9. (PMID: 22039016) Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. (PMID: 30523282) J Clin Endocrinol Metab. 2020 Jun 1;105(6):. (PMID: 32173759) N Engl J Med. 2018 Jan 11;378(2):158-168. (PMID: 29320654) J Neuroimmune Pharmacol. 2010 Jun;5(2):189-97. (PMID: 20107924) Arch Immunol Ther Exp (Warsz). 2014 Dec;62(6):449-58. (PMID: 24879097) Cell. 2020 Aug 6;182(3):655-671.e22. (PMID: 32603654) J Neuroimmunol. 2009 Oct 30;215(1-2):10-24. (PMID: 19692128) J Virol. 2007 Feb;81(4):2002-11. (PMID: 17151096) Cancer Invest. 2017 Aug 9;35(7):443-455. (PMID: 28548891) J Immunol. 2009 Mar 15;182(6):3469-81. (PMID: 19265125) Nature. 2018 Jul;559(7714):363-369. (PMID: 29950727) Curr Ther Res Clin Exp. 2019 Oct 28;91:45-51. (PMID: 31871508) N Engl J Med. 2009 Aug 27;361(9):888-98. (PMID: 19710487) J Exp Med. 2001 Aug 20;194(4):481-9. (PMID: 11514604) Nat Rev Immunol. 2020 Jan;20(1):25-39. (PMID: 31570880) J Cancer Res Clin Oncol. 2022 Jul;148(7):1711-1720. (PMID: 34347128) J Oncol Pharm Pract. 2019 Apr;25(3):551-557. (PMID: 29207939) J Exp Med. 2009 Jul 6;206(7):1457-64. (PMID: 19564351) J Clin Oncol. 2017 Dec 1;35(34):3815-3822. (PMID: 28915085) J Clin Invest. 2018 Apr 2;128(4):1338-1354. (PMID: 29480817) J Immunol. 2017 Mar 15;198(6):2249-2259. (PMID: 28167631) Cell. 2017 Sep 7;170(6):1120-1133.e17. (PMID: 28803728) Cell. 2020 Jul 23;182(2):447-462.e14. (PMID: 32758418) Handb Clin Neurol. 2014;122:173-89. (PMID: 24507518) Oncoimmunology. 2017 Jan 20;6(2):e1273300. (PMID: 28344884) J Dermatol Sci. 2017 Apr;86(1):71-73. (PMID: 28069323) J Clin Oncol. 2019 Oct 20;37(30):2738-2745. (PMID: 31163011) J Transl Med. 2018 Apr 11;16(1):94. (PMID: 29642948) J Immunother. 2012 Feb-Mar;35(2):169-78. (PMID: 22306905) Nat Rev Drug Discov. 2012 Oct;11(10):763-76. (PMID: 23023676) Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. (PMID: 32246128) Cell. 2015 Dec 3;163(6):1400-12. (PMID: 26607794) Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3013-7. (PMID: 11867713) JAMA Oncol. 2018 Dec 1;4(12):1721-1728. (PMID: 30242316) Nat Immunol. 2015 May;16(5):448-57. (PMID: 25898198) Mol Cancer Res. 2011 Dec;9(12):1658-67. (PMID: 21976712) Front Oncol. 2018 Mar 22;8:80. (PMID: 29623257) Cureus. 2020 Apr 6;12(4):e7565. (PMID: 32382467) Gastroenterology. 2004 Apr;126(4):989-96; discussion 947. (PMID: 15057738) N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431) Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54. (PMID: 23983039) J Vis Exp. 2014 Apr 15;(86):. (PMID: 24797125) |
| معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS; K01 AI163412 United States AI NIAID NIH HHS; R01 HL141966 United States HL NHLBI NIH HHS; R01 HL143520 United States HL NHLBI NIH HHS; K08 AR079587 United States AR NIAMS NIH HHS; R50 CA243707 United States CA NCI NIH HHS; P50 CA221703 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: EAE; TC1/TC17; Th1/Th17; Th17 memory; arthritis; colitis; immune checkpoint blockade; immunity; interleukin-6; melanoma; toxicity |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04940299 |
| المشرفين على المادة: | 0 (Immunologic Factors) 0 (Interleukin-6) |
| تواريخ الأحداث: | Date Created: 20220510 Date Completed: 20220512 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| مُعرف محوري في PubMed: | PMC9221568 |
| DOI: | 10.1016/j.ccell.2022.04.004 |
| PMID: | 35537412 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1878-3686 |
|---|---|
| DOI: | 10.1016/j.ccell.2022.04.004 |